Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
about
Cholinesterase inhibitors for Parkinson's disease dementiaModeling accuracy and variability of motor timing in treated and untreated Parkinson's disease and healthy controlsPoetic talent unmasked by treatment of Parkinson's disease.Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Tonic dopaminergic stimulation impairs associative learning in healthy subjects.The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients.Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation.MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway.Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.Qualitative evaluation of adherence therapy in Parkinson's disease: a multidirectional model.A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.Dopamine D2 receptor and β-arrestin 2 mediate Amyloid-β elevation induced by anti-parkinson's disease drugs, levodopa and piribedil, in neuronal cellsAmelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's diseaseDopaminergic modulation of memory and affective processing in Parkinson depression.Rivastigmine in Parkinson's disease dementia.Neurotransmission in Parkinson's disease: beyond dopamine.Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"?Drug therapy of post-stroke aphasia: a review of current evidence.Cognitive impairment in nondemented Parkinson's disease.Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review.The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease.Sleep Disturbance May Alter White Matter and Resting State Functional Connectivities in Parkinson's Disease.The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease?Can levodopa prevent cognitive decline in patients with Parkinson's disease?Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism.Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease.The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans.Differential response in choice reaction time following apomorphine based on prior dopaminergic treatment.Levodopa: faster and better word learning in normal humans.Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy.Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial.l-Dopa/carbidopa intestinal gel and subthalamic nucleus stimulation: Effects on cognition and behavior.A Single Neonatal Exposure to BMAA in a Rat Model Produces Neuropathology Consistent with Neurodegenerative Diseases.Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients.The early course of affective and cognitive symptoms in de novo patients with Parkinson's disease.Deep brain stimulation of the subthalamic nucleus: All that glitters isn't gold?Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
P2860
Q24244668-DDBEF82A-C690-4BA7-8728-F7407ADBC8CCQ30429215-F2F15BB6-E552-4089-8E31-CC486ABA392CQ33424552-C4A6554A-DF85-466F-820F-AB274A95C2BEQ34307633-CB751B18-6056-4EA8-B3DB-F4B1A35F8376Q34553049-33E2B3EC-28AD-42A1-99FC-506429F5F4CEQ34925276-2D90E319-411F-4043-B4A6-976453456730Q35028363-BB1D74B0-14CC-41CE-A542-440AA6196B6FQ35484424-47CDB971-EC0C-4282-9957-69F6D7C13E35Q35863422-F0314892-CF64-46CE-8FFB-86CDF2B7D0C9Q35867684-43287EBE-11D0-44A1-9D75-CB058B1A7BD5Q36118555-24AFB7B9-A376-45D0-BA26-35CBE74229F3Q36295526-71801B24-7844-45BF-AE73-AC5B5D90F931Q36709824-FAEF227E-9A7E-4A2C-89DA-73C6C9CBCA5FQ37248904-45B9D28C-F55D-474A-828C-2FE20C9B34C3Q37556550-4EEEFE77-7CC7-403A-BE35-75AEC6F263ABQ37668684-39632233-B380-4EB6-8767-EF15E0A9C6C1Q37736512-887E7E29-E994-4C83-B941-AD6D49B366E5Q37862242-810593FF-E797-44B4-B5E9-E7720F41897EQ37892977-2C150E4A-E50A-4629-ABF6-8B29812FA4E5Q37918433-32B87530-6957-43C7-BCF6-128487B5E4E8Q37968511-FA7F56F2-1953-4CD3-B993-BDF939210729Q38156172-A596E4A3-443D-4365-9C70-30A14AB2C71DQ38206495-82D29C27-232B-4F75-9C64-491C0F5BF7E0Q38404255-5BA683ED-7D65-406A-8EF8-CB3BA25D035EQ38492172-D3FEB21E-EF55-4D0F-B90B-C711E5AFE42BQ39199825-BB6D1A67-EF3B-4939-B3A6-8719FAF7A529Q40955579-163257D8-9843-4FA9-9109-11E200A7150DQ42496308-C5BC092C-FD4D-438D-AF84-65CF8E868595Q43447196-7C787021-8804-4EFC-815C-D5EAAF00A5A5Q44393705-D7CAFECD-0855-4BBF-8643-7DE09AB8CEA3Q44841414-58EBC042-4E55-4578-9F9F-9D968AA4F78AQ44965437-01201A6B-9162-4FA6-86B1-3B7B266897C4Q45197260-4ED1B061-D0E6-42D9-ABEA-D0A2F7EC5171Q46328005-36AF3B0E-84A7-4ECD-AA62-03ADD5C925B9Q47140289-5A86FAE5-7655-4A02-82C1-BC3BD8417897Q47891276-13D1D629-4D72-4921-8AE5-34201A94A55AQ48259976-3763BA88-22EA-4803-A1DC-99B22D1A886BQ48320702-B3335AD5-A400-4116-A942-69B12AB48621Q48345426-2AD6541D-BB8B-4D4E-BA6F-930F24B58749Q48834526-ED9E15A8-DB05-4353-A181-D0D5AD6ECAE0
P2860
Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Chronic effects of dopaminergi ...... previously untreated patients.
@en
type
label
Chronic effects of dopaminergi ...... previously untreated patients.
@en
prefLabel
Chronic effects of dopaminergi ...... previously untreated patients.
@en
P2093
P2860
P1433
P1476
Chronic effects of dopaminergi ...... previously untreated patients.
@en
P2093
Barbanoj M
Berthier ML
Estévez-González A
García-Sánchez C
Gironell A
Kulisevsky J
Pascual-Sedano B
P2860
P304
P356
10.1002/1531-8257(200007)15:4<613::AID-MDS1005>3.0.CO;2-F
P407
P577
2000-07-01T00:00:00Z